NASDAQ:STIM

Neuronetics - STIM Stock Forecast, Price & News

$4.46

-0.01 (-0.22%)

(As of 08/12/2022 12:00 AM ET)

Add

Compare

Today's Range: $4.38
▼
$4.52
50-Day Range: $2.92
▼
$4.66
52-Week Range: $1.98
▼
$8.88

Volume: 120,343 shs
Average Volume: 1.64 million shs
Market Capitalization: $120.51 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $10.50

Neuronetics MarketRank™ Forecast

Analyst Rating: Hold
2.33 Rating Score
Upside/Downside: 135.4% Upside
$10.50 Price Target
Short Interest: Healthy
2.51% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.89
Based on 12 Articles This Week
Insider Trading: Balanced
Insiders Both Buying and Selling
Proj. Earnings Growth: Growing
From ($1.65) to ($1.49) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.17 out of 5 stars

Medical Sector

489th out of 1,117 stocks

Surgical & Medical Instruments Industry

52nd out of 113 stocks

3.2

Analyst's Opinion

Consensus Rating
Neuronetics has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 1 buy rating, 2 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $10.50, Neuronetics has a forecasted upside of 135.4% from its current price of $4.46.
Amount of Analyst Coverage
Neuronetics has received no research coverage in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
2.51% of the float of Neuronetics has been sold short.
Short Interest Ratio / Days to Cover
Neuronetics has a short interest ratio ("days to cover") of 0.8, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Neuronetics has recently increased by 24.75%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Neuronetics does not currently pay a dividend.
Dividend Growth
Neuronetics does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for STIM.

3.3

News and Social Media Coverage

News Sentiment
Neuronetics has a news sentiment score of 0.89. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.59 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 12 news articles for Neuronetics this week, compared to 3 articles on an average week.
Search Interest
8 people have searched for STIM on MarketBeat in the last 30 days. This is an increase of 700% compared to the previous 30 days.
MarketBeat Follows
Only 2 people have added Neuronetics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Neuronetics insiders have sold just slightly more of their company's stock than they have bought. Specifically, they have bought $275,932.00 in company stock and sold $293,135.00 in company stock. It is common for insiders to sell company stock at intervals simply to diversify their holdings.
Percentage Held by Insiders
Only 5.20% of the stock of Neuronetics is held by insiders.
Percentage Held by Institutions
75.18% of the stock of Neuronetics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Neuronetics are expected to grow in the coming year, from ($1.65) to ($1.49) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Neuronetics is -3.19, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Neuronetics is -3.19, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Neuronetics has a P/B Ratio of 1.76. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Neuronetics (NASDAQ:STIM) Stock

Neuronetics, Inc., a commercial stage medical technology company, designs, develops, and markets products for patients with neurohealth disorders in the United States and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder. Its NeuroStar Advanced Therapy System uses transcranial magnetic stimulation to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company sells its products through its sales and customer support team to psychiatrists. Neuronetics, Inc. was incorporated in 2001 and is headquartered in Malvern, Pennsylvania.

Neuronetics Stock Performance

NASDAQ:STIM traded down $0.01 during trading on Friday, reaching $4.46. 120,343 shares of the company's stock were exchanged, compared to its average volume of 422,742. The company has a debt-to-equity ratio of 0.46, a current ratio of 5.02 and a quick ratio of 4.64. The business has a 50 day moving average price of $3.67 and a 200-day moving average price of $3.20. The stock has a market capitalization of $120.52 million, a P/E ratio of -3.19 and a beta of 2.09. Neuronetics has a fifty-two week low of $1.98 and a fifty-two week high of $8.88.

Neuronetics (NASDAQ:STIM - Get Rating) last posted its earnings results on Thursday, May 12th. The company reported ($0.41) earnings per share for the quarter, hitting analysts' consensus estimates of ($0.41). Neuronetics had a negative return on equity of 46.12% and a negative net margin of 62.44%. The business had revenue of $14.18 million for the quarter, compared to analyst estimates of $13.20 million. During the same period in the previous year, the firm earned ($0.31) EPS. Sell-side analysts forecast that Neuronetics will post -1.65 earnings per share for the current fiscal year.

Insider Buying and Selling at Neuronetics

In related news, major shareholder Cannell Capital Llc acquired 15,369 shares of the firm's stock in a transaction on Friday, May 20th. The shares were purchased at an average cost of $2.41 per share, for a total transaction of $37,039.29. Following the completion of the acquisition, the insider now directly owns 3,393,063 shares in the company, valued at $8,177,281.83. The purchase was disclosed in a filing with the SEC, which is available at this link. In other news, CEO Keith J. Sullivan sold 63,466 shares of the stock in a transaction that occurred on Monday, July 18th. The stock was sold at an average price of $3.72, for a total transaction of $236,093.52. Following the transaction, the chief executive officer now owns 850,999 shares in the company, valued at $3,165,716.28. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, major shareholder Cannell Capital Llc purchased 15,369 shares of the company's stock in a transaction that occurred on Friday, May 20th. The shares were purchased at an average cost of $2.41 per share, with a total value of $37,039.29. Following the completion of the acquisition, the insider now owns 3,393,063 shares in the company, valued at approximately $8,177,281.83. The disclosure for this purchase can be found here. In the last quarter, insiders acquired 110,632 shares of company stock valued at $275,932 and sold 79,533 shares valued at $293,135. Insiders own 5.20% of the company's stock.

Receive STIM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Neuronetics and its competitors with MarketBeat's FREE daily newsletter.

STIM Stock News Headlines

August 11, 2022 | benzinga.com

Despite Competition This Analyst Finds BrainsWay Attractive - Benzinga

August 8, 2022 | finance.yahoo.com

Neuronetics (STIM) Just Flashed Golden Cross Signal: Do You Buy? - Yahoo Finance

August 8, 2022 | finance.yahoo.com

Neuronetics (STIM) Just Flashed Golden Cross Signal: Do You Buy?

August 6, 2022 | americanbankingnews.com

Q3 2022 EPS Estimates for Neuronetics, Inc. Boosted by Analyst (NASDAQ:STIM)

August 4, 2022 | seekingalpha.com

Neuronetics Inc (STIM) CEO Keith Sullivan on Q2 2022 Results - Earnings Call Transcript

August 2, 2022 | finance.yahoo.com

Neuronetics, Inc. (STIM) Q2 2022 Earnings Call Transcript

August 2, 2022 | investing.com

Neuronetics Tops Q2 EPS by 2c By Investing.com - Investing.com

August 2, 2022 | seekingalpha.com

Neuronetics GAAP EPS of -$0.39 beats by $0.02, revenue of $16.3M beats by $0.84M - Seeking Alpha

August 2, 2022 | ca.investing.com

Neuronetics Tops Q2 EPS by 2c By Investing.com - Investing.com Canada

August 2, 2022 | benzinga.com

Recap: Neuronetics Q2 Earnings - Benzinga

August 2, 2022 | globenewswire.com

Neuronetics Reports Second Quarter 2022 Financial and Operating Results - GlobeNewswire

August 2, 2022 | finance.yahoo.com

Neuronetics Reports Second Quarter 2022 Financial and Operating Results

August 1, 2022 | benzinga.com

Neuronetics's Earnings: A Preview - Benzinga

August 1, 2022 | americanbankingnews.com

Neuronetics (STIM) Scheduled to Post Quarterly Earnings on Tuesday

July 29, 2022 | bizjournals.com

Philadelphia biotech news: Updates from Marken, Strata Skin Sciences, AmerisourceBergen and more - Philadelphia Business Journal - The Business Journals

July 28, 2022 | finance.yahoo.com

Neuronetics to Present at the Canaccord Genuity 42nd Annual Growth Conference

July 28, 2022 | americanbankingnews.com

Stephen Furlong Sells 13,321 Shares of Neuronetics, Inc. (NASDAQ:STIM) Stock

July 25, 2022 | globenewswire.com

Neuronetics and Alleviant Health Centers Announce Exclusive Partnership - GlobeNewswire

July 25, 2022 | finance.yahoo.com

Neuronetics and Alleviant Health Centers Announce Exclusive Partnership

July 22, 2022 | bizjournals.com

Lab Notes: FDA approves Incyte's vitiligo treatment; Neuronetics gets a 'big win' - The Business Journals

July 22, 2022 | americanbankingnews.com

Keith J. Sullivan Sells 63,466 Shares of Neuronetics, Inc. (NASDAQ:STIM) Stock

July 19, 2022 | morningstar.com

Neuronetics gets another FDA clearance for transcranial magnetic stimulation system; shares jump 22% - Morningstar

July 19, 2022 | benzinga.com

Thinking about buying stock in Exela Technologies, Applied Blockchain, Neuronetics, Apellis Pharmaceutica - Benzinga

July 19, 2022 | benzinga.com

Neuronetics Announces NeuroStar Advanced Therapy Receives FDA Clearance For Treatment Of Anxious Depressi - Benzinga

July 19, 2022 | finance.yahoo.com

Read Why Neuronetics Shares Are Trading Higher Today

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive STIM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Neuronetics and its competitors with MarketBeat's FREE daily newsletter.

STIM Company Calendar

Last Earnings: 11/09/2021
Today: 8/13/2022
Next Earnings (Estimated): 11/08/2022
Fiscal Year End: 12/31/2022

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Surgical & medical instruments
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:STIM
CUSIP: N/A
CIK: 1227636
Web: www.neurostar.com
Phone: (610) 640-4202
Fax: 610-640-4206
Employees: 175
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $10.50
High Stock Price Forecast: $12.00
Low Stock Price Forecast: $9.00
Forecasted Upside/Downside: +135.4%
Consensus Rating: Hold
Rating Score (0-4): 2.33
Research Coverage: 3 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.40)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-31,190,000.00
Net Margins: -62.44%
Pretax Margin: -62.44%
Return on Equity: -46.12%
Return on Assets: -27.58%

Debt

Debt-to-Equity Ratio: 0.46
Current Ratio: 5.02
Quick Ratio: 4.64

Sales & Book Value

Annual Sales: $55.31 million
Price / Sales: 2.18
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $2.53 per share
Price / Book: 1.76

Miscellaneous

Outstanding Shares: 27,020,000
Free Float: 25,618,000
Market Cap: $120.51 million
Optionable: Not Optionable
Beta: 2.09

Key Executives

Mr. Keith J. Sullivan (Age 64)
Pres, CEO & Director
Comp: $1.25M
Mr. Stephen J. Furlong M.S. (Age 57)
Sr. VP, CFO & Treasurer
Comp: $680.02k
Mr. W. Andrew Macan (Age 49)
Sr. VP, Gen. Counsel, Chief Compliance Officer, Sec. & Member of Office of the Pres
Comp: $548.83k
Ms. Sara Grubbs
VP of Sales
Ms. Claire Sears
VP of Marketing
Ms. Kara Thornton
VP of HR & Sr. Director

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

STIM Stock - Frequently Asked Questions

Should I buy or sell Neuronetics stock right now?: 3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Neuronetics in the last twelve months. There are currently 2 hold ratings and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" STIM shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in STIM, but not buy additional shares or sell existing shares.
View STIM analyst ratings or view top-rated stocks.
What is Neuronetics' stock price forecast for 2022?: 3 equities research analysts have issued 12 month price targets for Neuronetics' shares. Their STIM share price forecasts range from $9.00 to $12.00. On average, they expect the company's stock price to reach $10.50 in the next year. This suggests a possible upside of 135.4% from the stock's current price.
View analysts price targets for STIM or view top-rated stocks among Wall Street analysts.
How have STIM shares performed in 2022?: Neuronetics' stock was trading at $4.46 at the beginning of the year. Since then, STIM stock has increased by 0.0% and is now trading at $4.46.
View the best growth stocks for 2022 here.
When is Neuronetics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 8th 2022.
View our STIM earnings forecast.
How were Neuronetics' earnings last quarter?: Neuronetics, Inc. (NASDAQ:STIM) issued its quarterly earnings results on Tuesday, November, 9th. The company reported ($0.31) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.28) by $0.03. The firm had revenue of $13.80 million for the quarter, compared to analyst estimates of $13.80 million. Neuronetics had a negative trailing twelve-month return on equity of 46.12% and a negative net margin of 62.44%. During the same quarter last year, the business posted ($0.18) EPS.
What guidance has Neuronetics issued on next quarter's earnings?: Neuronetics updated its third quarter 2022 earnings guidance on Tuesday, August, 9th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $14.50 million-$15.50 million, compared to the consensus revenue estimate of $14.85 million.

What other stocks do shareholders of Neuronetics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Neuronetics investors own include SCYNEXIS (SCYX), Inovio Pharmaceuticals (INO), Novavax (NVAX), Gilead Sciences (GILD), iBio (IBIO), Onconova Therapeutics (ONTX), Pfizer (PFE), Tonix Pharmaceuticals (TNXP), Vaxart (VXRT) and Acasti Pharma (ACST).
When did Neuronetics IPO?: (STIM) raised $75 million in an initial public offering (IPO) on Thursday, June 28th 2018. The company issued 5,000,000 shares at $14.00-$16.00 per share. Piper Jaffray and William Blair served as the underwriters for the IPO and Canaccord Genuity, BTIG and JMP Securities were co-managers.
What is Neuronetics' stock symbol?: Neuronetics trades on the NASDAQ under the ticker symbol "STIM."
Who are Neuronetics' major shareholders?: Neuronetics' stock is owned by many different retail and institutional investors. Top institutional shareholders include Millrace Asset Group Inc. (2.36%), Brandywine Global Investment Management LLC (1.58%), Premier Fund Managers Ltd (1.12%), Allspring Global Investments Holdings LLC (0.85%), Envestnet Asset Management Inc. (0.40%) and Renaissance Technologies LLC (0.32%). Insiders that own company stock include Brian E Farley, Bruce Joseph Shook, Cannell Capital Llc, Christopher Thatcher, Daniel Guthrie, Gregory Harper, Keith J Sullivan, Paul Liberman, Robert Cascella, Sheryl L Conley, Stephen Furlong, Stephen M Campe and William Andrew Macan.
View institutional ownership trends.
How do I buy shares of Neuronetics?: Shares of STIM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Neuronetics' stock price today?: One share of STIM stock can currently be purchased for approximately $4.46.
How much money does Neuronetics make?: Neuronetics (NASDAQ:STIM) has a market capitalization of $120.52 million and generates $55.31 million in revenue each year. The company earns $-31,190,000.00 in net income (profit) each year or ($1.40) on an earnings per share basis.
How many employees does Neuronetics have?: The company employs 175 workers across the globe.
How can I contact Neuronetics?: Neuronetics' mailing address is 3222 PHOENIXVILLE PIKE, MALVERN PA, 19355. The official website for the company is www.neurostar.com. The company can be reached via phone at (610) 640-4202, via email at ir@neuronetics.com, or via fax at 610-640-4206.

This page (NASDAQ:STIM) was last updated on 8/13/2022 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Neuronetics - STIM Stock Forecast, Price & News

Neuronetics MarketRank™ Forecast

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Neuronetics (NASDAQ:STIM) Stock

Neuronetics Stock Performance

Insider Buying and Selling at Neuronetics

STIM Stock News Headlines

STIM Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

STIM Stock - Frequently Asked Questions

Should I buy or sell Neuronetics stock right now?

What is Neuronetics' stock price forecast for 2022?

How have STIM shares performed in 2022?

When is Neuronetics' next earnings date?

How were Neuronetics' earnings last quarter?

What guidance has Neuronetics issued on next quarter's earnings?

What other stocks do shareholders of Neuronetics own?

When did Neuronetics IPO?

What is Neuronetics' stock symbol?

Who are Neuronetics' major shareholders?

How do I buy shares of Neuronetics?

What is Neuronetics' stock price today?

How much money does Neuronetics make?

How many employees does Neuronetics have?

How can I contact Neuronetics?

MarketBeat Resources

Premium Research Tools

Market Data and Calendars

Investing Education and Resources

Overall MarketRank^™